Literature DB >> 11414657

The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.

K A Krobert1, T Bach, T Syversveen, A M Kvingedal, F O Levy.   

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) receptor pre-mRNA is alternatively spliced in human tissue to produce three splice variants, h5-HT7(a), h5-HT7(b) and h5-HT7(d), which differ only in their carboxyl terminal tails. Using membranes from transiently and stably transfected HEK293 cells expressing the three recombinant h5-HT7 splice variants we compared their pharmacological profiles and ability to activate adenylyl cyclase. Using PCR on cDNA derived from various human tissues, the 5-HT7(a) and 5-HT7(b) splice variants were detected in every tissue examined. The h5-HT7(d) splice variant was detected in 13 of 16 tissues examined, with predominant expression in the heart, small intestine, colon, ovary and testis. All three h5-HT7 splice variants displayed high affinity binding for [3H]5-HT (pKd=8.8-8.9) in the presence and absence of 100 microM GTP and had similar binding affinities for all 17 ligands evaluated. In HEK293 cells expressing similar, high levels of receptor (approximately 10,000 fmol/mg protein), 5-CT (5-carboxamidotryptamine), 5-MeOT (5-methoxytryptamine) and 5-HT were full agonists while 8-OH-DPAT ((2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin) was a partial agonist with relative efficacy of approximately 0.8. Even at this high receptor level, EC50 values for stimulation of adenylyl cyclase were 10- to 50-fold higher than the Kd values, indicating a lack of spare receptors. No significant differences in coupling to adenylyl cyclase were observed between the three splice variants over a wide range of receptor expression levels. For antagonists, binding affinities determined by displacement of [3H]5-HT binding and by competitive inhibition of 5-HT-stimulated adenylyl cyclase activity were essentially identical amongst the splice variants. These studies indicate that the three human splice variants are pharmacologically indistinguishable and that modifications of the carboxyl tail do not influence coupling to adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414657     DOI: 10.1007/s002100000369

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  45 in total

1.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileum.

Authors:  Bishwa R Tuladhar; Lanbo Ge; Robert J Naylor
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 3.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

Review 4.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

Review 5.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

6.  Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines.

Authors:  Cécile Mahé; Michel Bernhard; Ionel Bobirnac; Corinna Keser; Erika Loetscher; Dominik Feuerbach; Kumlesh K Dev; Philippe Schoeffter
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

7.  Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 8.  Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.

Authors:  Anne Matthys; Guy Haegeman; Kathleen Van Craenenbroeck; Peter Vanhoenacker
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 9.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

Review 10.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.